Pipeline updates are highly awaited events in the
pharma/biotech sector as they play an important role in deciding
whether or not to invest in a particular company. These updates
provide information on experimental drugs and at times provide an
insight into the commercial potential of the candidate once it is
successfully developed and commercialized.
FOREST LABS A (FRX): Free Stock Analysis
INTERCEPT PHARM (ICPT): Free Stock Analysis
JAZZ PHARMACEUT (JAZZ): Free Stock Analysis
LANNETT INC (LCI): Free Stock Analysis Report
To read this article on Zacks.com click here.
Intercept Pharmaceuticals, Inc.
), a biopharmaceutical company, announced that it will be
providing an update on its pipeline on Jan 9, 2014. The update
will primarily focus on the phase III POISE study on its lead
candidate, obeticholic acid. The update will also include
top-line results from the OBADIAH and PESTO studies.
Intercept Pharma is developing obeticholic acid for the treatment
of primary biliary cirrhosis (PBC). Intercept Pharma is currently
expecting results from the POISE study in the second quarter of
2014. Patients completing twelve months of treatment with
obeticholic acid are eligible to participate in an open label
safety extension study for another five years.
We note that Intercept Pharma is also developing obeticholic acid
for the treatment of chronic liver and other diseases. Intercept
Pharma is developing the candidate for the treatment of primary
bile acid diarrhoea (PBAD) in the phase IIa OBADIAH study. The
study is evaluating whether obeticholic acid can stimulate the
release of FGF19 in patients suffering from PBAD. Meanwhile, the
phase IIa PESTO study is evaluating obeticholic acid in patients
suffering from portal hypertension.
Apart from obeticholic acid, Intercept Pharma also has INT-767
(chronic kidney diseases) and INT-777 (type II diabetes and
associated metabolic disorders) in its pipeline. We expect
investor focus to remain on the company's pipeline going forward.
Intercept Pharma currently carries a Zacks Rank #4 (Sell). Some
better-ranked stocks include
Lannett Company, Inc.
Forest Laboratories Inc.
). All the stocks carry a Zacks Rank #1 (Strong Buy).